A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIA non-small-cell lung cancer. Eastern Cooperative Oncology Group.

@article{Keller2000ART,
  title={A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIA non-small-cell lung cancer. Eastern Cooperative Oncology Group.},
  author={Seth Keller and Sudeshna Adak and Henry Wagner and Arnold M. Herskovic and Ritsuko Komaki and Burke J. Brooks and Michael C. Perry and Robert B. Livingston and David H. Johnson},
  journal={The New England journal of medicine},
  year={2000},
  volume={343 17},
  pages={1217-22}
}
BACKGROUND We conducted a randomized trial to determine whether combination chemotherapy plus thoracic radiotherapy is superior to thoracic radiotherapy alone in prolonging survival and preventing local recurrence in patients with completely resected stage II or IIIa non-small-cell lung cancer. METHODS After surgical staging and resection of the tumor (usually by lobectomy or pneumonectomy), the patients were randomly assigned to receive either four 28-day cycles of cisplatin (60 mg per… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 73 extracted citations

EGFR R497K polymorphism is a favorable prognostic factor for advanced lung cancer

Journal of Cancer Research and Clinical Oncology • 2008
View 2 Excerpts
Highly Influenced

Similar Papers

Loading similar papers…